Cargando…

Plasma vascular endothelial growth factor 165 in advanced non-small cell lung cancer

Currently, there is no serum marker that is routinely recommended for lung cancer. Therefore, the aim of the present study was to demonstrate that plasma vascular endothelial growth factor 165 (VEGF 165) may be a potential marker for advanced lung cancer. Lung cancer is the leading cause of cancer-r...

Descripción completa

Detalles Bibliográficos
Autores principales: ABDALLAH, AHMED, BELAL, MOHAMED, EL BASTAWISY, AHMED, GAAFAR, RABAB
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049695/
https://www.ncbi.nlm.nih.gov/pubmed/24932301
http://dx.doi.org/10.3892/ol.2014.2016
_version_ 1782319852098158592
author ABDALLAH, AHMED
BELAL, MOHAMED
EL BASTAWISY, AHMED
GAAFAR, RABAB
author_facet ABDALLAH, AHMED
BELAL, MOHAMED
EL BASTAWISY, AHMED
GAAFAR, RABAB
author_sort ABDALLAH, AHMED
collection PubMed
description Currently, there is no serum marker that is routinely recommended for lung cancer. Therefore, the aim of the present study was to demonstrate that plasma vascular endothelial growth factor 165 (VEGF 165) may be a potential marker for advanced lung cancer. Lung cancer is the leading cause of cancer-related mortality worldwide, therefore, it is important to develop novel diagnostic techniques. The present prospective case control study included two groups of patients; a control group of healthy volunteers and a second group of patients with advanced non-small cell lung cancer (NSCLC). The plasma VEGF 165 levels were measured at baseline by ELISA prior to the first-line gemcitabine-cisplatin regimen. The high VEGF 165 expression level cut-off was >703 pg/ml, and the primary endpoint was used to compare the plasma VEGF 165 levels between the NSCLC patients and the control group subjects. The secondary endpoint was used to identify the correlations between high VEGF 165 levels and; clinical response (CR), progression-free survival (PFS) and overall survival (OS) in the advanced NSCLC patients. In total, patients with advanced NSCLC (n=35) were compared with a control group of age- and gender-matched healthy subjects (n=34). The follow-up period was between Oct 2009 and Oct 2012, with a median follow-up time of 10.5 months. The median plasma VEGF 165 level was 707 pg/ml in the NSCLC patients versus 48 pg/ml in the healthy control subjects (P<0.001). However, no significant correlation was found between the plasma VEGF 165 levels and CR (P<0.5), median PFS (P=1.00) or OS (P=0.70). Therefore, it was concluded that plasma VEGF 165 may serve as a potential diagnostic marker for advanced NSCLC.
format Online
Article
Text
id pubmed-4049695
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-40496952014-06-13 Plasma vascular endothelial growth factor 165 in advanced non-small cell lung cancer ABDALLAH, AHMED BELAL, MOHAMED EL BASTAWISY, AHMED GAAFAR, RABAB Oncol Lett Articles Currently, there is no serum marker that is routinely recommended for lung cancer. Therefore, the aim of the present study was to demonstrate that plasma vascular endothelial growth factor 165 (VEGF 165) may be a potential marker for advanced lung cancer. Lung cancer is the leading cause of cancer-related mortality worldwide, therefore, it is important to develop novel diagnostic techniques. The present prospective case control study included two groups of patients; a control group of healthy volunteers and a second group of patients with advanced non-small cell lung cancer (NSCLC). The plasma VEGF 165 levels were measured at baseline by ELISA prior to the first-line gemcitabine-cisplatin regimen. The high VEGF 165 expression level cut-off was >703 pg/ml, and the primary endpoint was used to compare the plasma VEGF 165 levels between the NSCLC patients and the control group subjects. The secondary endpoint was used to identify the correlations between high VEGF 165 levels and; clinical response (CR), progression-free survival (PFS) and overall survival (OS) in the advanced NSCLC patients. In total, patients with advanced NSCLC (n=35) were compared with a control group of age- and gender-matched healthy subjects (n=34). The follow-up period was between Oct 2009 and Oct 2012, with a median follow-up time of 10.5 months. The median plasma VEGF 165 level was 707 pg/ml in the NSCLC patients versus 48 pg/ml in the healthy control subjects (P<0.001). However, no significant correlation was found between the plasma VEGF 165 levels and CR (P<0.5), median PFS (P=1.00) or OS (P=0.70). Therefore, it was concluded that plasma VEGF 165 may serve as a potential diagnostic marker for advanced NSCLC. D.A. Spandidos 2014-06 2014-03-31 /pmc/articles/PMC4049695/ /pubmed/24932301 http://dx.doi.org/10.3892/ol.2014.2016 Text en Copyright © 2014, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Articles
ABDALLAH, AHMED
BELAL, MOHAMED
EL BASTAWISY, AHMED
GAAFAR, RABAB
Plasma vascular endothelial growth factor 165 in advanced non-small cell lung cancer
title Plasma vascular endothelial growth factor 165 in advanced non-small cell lung cancer
title_full Plasma vascular endothelial growth factor 165 in advanced non-small cell lung cancer
title_fullStr Plasma vascular endothelial growth factor 165 in advanced non-small cell lung cancer
title_full_unstemmed Plasma vascular endothelial growth factor 165 in advanced non-small cell lung cancer
title_short Plasma vascular endothelial growth factor 165 in advanced non-small cell lung cancer
title_sort plasma vascular endothelial growth factor 165 in advanced non-small cell lung cancer
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049695/
https://www.ncbi.nlm.nih.gov/pubmed/24932301
http://dx.doi.org/10.3892/ol.2014.2016
work_keys_str_mv AT abdallahahmed plasmavascularendothelialgrowthfactor165inadvancednonsmallcelllungcancer
AT belalmohamed plasmavascularendothelialgrowthfactor165inadvancednonsmallcelllungcancer
AT elbastawisyahmed plasmavascularendothelialgrowthfactor165inadvancednonsmallcelllungcancer
AT gaafarrabab plasmavascularendothelialgrowthfactor165inadvancednonsmallcelllungcancer